Establishment Labs (ESTA) Scheduled to Post Quarterly Earnings on Wednesday

Establishment Labs (NASDAQ:ESTA) is scheduled to be releasing its earnings data after the market closes on Wednesday, May 8th. Analysts expect Establishment Labs to post earnings of ($0.65) per share for the quarter. Establishment Labs has set its FY 2024 guidance at EPS.Investors interested in listening to the company’s conference call can do so using this link.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.16. Establishment Labs had a negative net margin of 47.53% and a negative return on equity of 357.81%. The company had revenue of $31.60 million for the quarter, compared to analyst estimates of $31.44 million. During the same quarter last year, the business earned ($0.55) EPS. Establishment Labs’s revenue for the quarter was down 27.9% on a year-over-year basis. On average, analysts expect Establishment Labs to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Establishment Labs Stock Performance

Shares of Establishment Labs stock opened at $52.83 on Monday. The company has a current ratio of 3.06, a quick ratio of 1.67 and a debt-to-equity ratio of 10.26. The business’s fifty day moving average price is $49.44 and its 200 day moving average price is $37.01. Establishment Labs has a twelve month low of $16.96 and a twelve month high of $73.00.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Stephens reiterated an “overweight” rating and set a $47.00 target price on shares of Establishment Labs in a research note on Thursday, January 11th. Citigroup boosted their price objective on Establishment Labs from $49.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Mizuho lifted their target price on Establishment Labs from $50.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Finally, JPMorgan Chase & Co. upped their price target on Establishment Labs from $46.00 to $53.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $55.00.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.